Abstract
Toxicokinetic (TK) behavior of most chemicals is determined to a large extent by metabolism (xenobiotic-metabolizing enzymes). If metabolic processes were to be measured in in vitro cellular systems, it is of utmost importance to ensure that they are actually functional or at least incorporated in one way or another and at levels similar to those in vivo.
In this chapter, current and future experimental possibilities to develop and characterize cells capable of metabolism and having other important dispositional characteristics mimicking the in vivo situation are described. Consideration is also given to incorporating this information into tissue models, and some examples are presented, with special reference to the metabolic and disposition competence of the systems. In conclusion, in vitro cellular systems should be developed and validated in a much more detailed way, taking into account the early characterization of metabolism and other important kinetic processes, because the thorough characterization is the prerequisite for the validation and use of cellular systems for pharmacological and toxicological studies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Mentioned in an abstract of the ISSX International Conference in Istanbul, 2010 and in HepaRG product leaflets of Biopredic and Millipore.
References
Coecke S, Pelkonen O, Batista Leite S et al (2013) Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches. Toxicol In Vitro 27:1570–1577
Coecke S, Ahr H, Blaauboer BJ et al (2006) Metabolism: a bottleneck in in vitro toxicological test development: the report and recommendations of ECVAM workshop 54. Altern Lab Anim 34:49–84
Pelkonen O, Kapitulnik J, Gundert-Remy U, Boobis AR, Stockis A (2008) Local kinetics and dynamics of Xenobiotics. Crit Rev Toxicol 38:697–720
Park BK, Boobis A, Clarke S (2011) Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov 10:292–306
Adler S, Basketter D, Creton S et al (2011) Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010. Arch Toxicol 85:367–485
Tolonen A, Pelkonen O (2013) Analytical challenges for conducting rapid metabolism characterization for QIVIVE. Toxicology. doi:10.1016/j.tox.2013.08.010
Hartung T (2009) Toxicology for the twenty-first century. Nature 460:208–212
Hartung T, Hoffmann S (2009) Food for thought … on in silico methods in toxicology. ALTEX 26:155–166
Giacomini KM, Huang SM, Tweedie DJ et al (2010) International transporter consortium. Membrane transporters in drug development. Nat Rev Drug Discov 9:215–236
Wang YM, Ong SS, Chai SC, Chen T (2012) Role of CAR and PXR in xenobiotic sensing and metabolism. Expert Opin Drug Metab Toxicol 8:803–817
Wienkers LC, Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825–833
Zanger UM, Turpeinen M, Klein K et al (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093–1108
Gómez-Lechón MJ, Castell JV, Donato MT (2008) An update on metabolism studies using human hepatocytes in primary culture. Expert Opin Drug Metab Toxicol 4:837–854
Aninat C, Piton A, Glaise D et al (2006) Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34:75–83
Kanebratt KP, Andersson TB (2008) Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 36:1444–1452
Turpeinen M, Tolonen A, Chesne C et al (2009) Functional expression, inhibition and induction of cytochrome P450 (CYP) enzymes in human hepatoma HepaRG cells. Toxicol In Vitro 23:748–753
Le Vee M, Jigorel E, Glaise D et al (2006) Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur J Pharm Sci 28:109–117
Zanelli U, Caradonna NP, Hallifax D et al (2012) Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs. Drug Metab Dispos 40:104–110
Kanebratt KP, Andersson TB (2008) HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 36:137–145
Lübberstedt M, Müller-Vieira U, Mayer M et al (2011) HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. J Pharmacol Toxicol Methods 63:59–68
Rogue A, Lambert C, Spire C et al (2012) Interindividual variability in gene expression profiles in human hepatocytes and comparison with HepaRG cells. Drug Metab Dispos 40:151–158
Hoekstra R, Nibourg GA, van der Hoeven TV et al (2013) Phase 1 and phase 2 drug metabolism and bile acid production of HepaRG cells in a bioartificial liver in absence of dimethyl sulfoxide. Drug Metab Dispos 41:562–567
Hart SN, Li Y, Nakamoto K et al (2010) A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab Dispos 38:988–994
Andersson TB, Kanebratt KP, Kenna JG (2012) The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human. Expert Opin Drug Metab Toxicol 8:909–920
McGill MR, Yan HM, Ramachandran A et al (2011) HepaRG cells: a human model to study mechanisms of acetaminophen hepatotoxicity. Hepatology 53:974–982
Park BK, Pirmohamed M, Kitteringham NR (1995) The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 68:385–424
Ding X, Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43:149–173
Cencic A, Langerholc T (2010) Functional cell models of the gut and their applications in food microbiology—a review. Int J Food Microbiol 31(141 Suppl 1):S4–S14
Lancerholc T, Maragkoudakis PA, Wollgast J et al (2011) Novel and established intestinal cell line models—an indispensable tool in food science and nutrition. Trends Foof Sci Tech 22:11–20
Hayeshi R, Hilgendorf C, Artursson P et al (2008) Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci 18:383–396
Hubatsch I, Ragnarsson EG, Artursson P (2007) Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc 2:2111–2119
Wetmore BA, Wambaugh JF, Ferguson SS et al (2012) Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicol Sci 125:157–174
Korjamo T, Honkakoski P, Toppinen MR et al (2005) Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines. Eur J Pharm Sci 26:266–279
Pelkonen O, Turpeinen M, Hakkola J et al (2013) Preservation, induction or incorporation of metabolism into the in vitro cellular system—views to current opportunities and limitations. Toxicol In Vitro 27:1578–1583
Soldatow VY, LeCluyse EL, Griffith LG et al (2013) In vitro models for liver toxicity testing. Toxicol Res (Camb) 2:23–39
Ginai M, Elsby R, Hewitt CJ et al (2013) The use of bioreactors as in vitro models in pharmaceutical research. Drug Discov Today 18(19–20):922–935, pii: S1359-6446(13)00162-1
Zeilinger K, Schreiter T, Darnell M et al (2011) Scaling down of a clinical three-dimensional perfusion multicompartment hollow fiber liver bioreactor developed for extracorporeal liver support to an analytical scale device useful for hepatic pharmacological in vitro studies. Tissue Eng Part C Methods 17(5):549–556
Ulvestad M, Darnell M, Molden E et al (2012) Evaluation of organic anion-transporting polypeptide 1B1 and CYP3A4 activities in primary human hepatocytes and HepaRG cells cultured in a dynamic three-dimensional bioreactor system. J Pharmacol Exp Ther 343(1):145–156
Darnell M, Schreiter T, Zeilinger K et al (2011) Cytochrome P450-dependent metabolism in HepaRG cells cultured in a dynamic three-dimensional bioreactor. Drug Metab Dispos 39(7):1131–1138
Nibourg GA, Hoekstra R, van der Hoeven TV et al (2013) Increased hepatic functionality of the human hepatoma cell line HepaRG cultured in the AMC bioreactor. Int J Biochem Cell Biol 45(8):1860–1868
Gunness P, Mueller D, Shevchenko V et al (2013) 3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies. Toxicol Sci 33(1):67–78
Takahashi K, Tanabe K, Ohnuki M et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861–872
Baxter MA, Rowe C, Alder J et al (2010) Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening. Stem Cell Res 5(1):4–22
Scott CW, Peters MF, Dragan YP (2013) Human induced pluripotent stem cells and their use in drug discovery for toxicity testing. Toxicol Lett 219:49–58
Jozefczuk J, Prigione A, Chavez L, Adjaye J (2011) Comparative analysis of human embryonic stem cell and induced pluripotent stem cell-derived hepatocyte-like cells reveals current drawbacks and possible strategies for improved differentiation. Stem Cells Dev 20:1259–1275
Kia R, Sison RL, Heslop J et al (2013) Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet? Br J Clin Pharmacol 75(4):885–896
Hakkola J, Tanaka E, Pelkonen O (1998) Developmental expression of cytochrome P450 enzymes in human liver. Pharmacol Toxicol 82:209–217
Takebe T, Sekine K, Enomura M et al (2013) Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 499(7459):481–484. doi:10.1038/nature12271
Parkinson A, Ogilvie BW (2010) Biotransformation of xenobiotics. In: Klaassen CD (ed) Casarett and Doull’s toxicology: the basic science of poisons, 7th edn. McGraw-Hill, New York, pp 161–304
Pelkonen O, Tolonen A, Turpeinen M, Uusitalo J (2008) In vitro metabolism in preclinical drug development. In: Cox Gad S (ed) Preclinical development handbook: ADME and biopharmaceutical properties. Wiley, New York, pp 743–774, Chapter 21
Pelkonen O, Turpeinen M (2007) In vitro–in vivo extrapolation of hepatic clearance: biological tools, scaling factors, model assumptions and correct concentrations. Xenobiotica 37:1066–1089
Tolonen A, Turpeinen M, Pelkonen O (2009) Liquid chromatography-mass spectrometry in in vitro drug metabolite screening. Drug Discov Today 14:120–133
Pelkonen O, Tolonen A, Korjamo T et al (2009) From known knowns to known unknowns: predicting in vivo drug metabolites. Bioanalysis 1:393–414
Turpeinen M, Ghiciuc C, Orpitoui M et al (2007) Predictive value of animal models for human cytochrome P450 (CYP)-mediated enzymes: a comparative study in vitro. Xenobiotica 37:1367–1377
Pelkonen O, Turpeinen M, Hakkola J et al (2008) Inhibition and induction of human cytochrome P450 enzymes—current status. Arch Toxicol 82:667–715
Hukkanen J (2012) Induction of cytochrome P450 enzymes: a view on human in vivo findings. Expert Rev Clin Pharmacol 5(5):569–585
Johansson I, Ingelman-Sundberg M (2011) Genetic polymorphism and toxicology—with emphasis on cytochrome p450. Toxicol Sci 120(1):1–13
Faucette SR, Hawke RL, Lecluyse EL et al (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222–1230
Hesse LM, Venkatakrishnan K, Court MH et al (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176–1183
Walsky RL, Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647–660
Tolonen A, Petsalo A, Turpeinen M et al (2007) In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies. J Mass Spectrom 42:960–966
Alden PG, Plumb RS, Jones MD et al (2010) A rapid ultra-performance liquid chromatography/tandem mass spectrometric methodology for the in vitro analysis of pooled and cocktail cytochrome P450 assays. Rapid Commun Mass Spectrom 24:147–154
Wu X, Wang J, Tan L et al (2012) In vitro ADME profiling using high-throughput rapid-fire mass spectrometry: cytochrome p450 inhibition and metabolic stability assays. J Biomol Screen 17:761–772
An WF, Tolliday NJ (2009) Introduction: cell-based assays for high-throughput screening. Methods Mol Biol 486:1–12
Donato MT, Gómez-Lechón MJ (2013) Fluorescence-based screening of cytochrome P450 activities in intact cells. Methods Mol Biol 987:135–148
Edwards RJ, Boobis AR, Davies DS (2003) A strategy for investigating the CYP superfamily using targeted antibodies is a paradigm for functional genomic studies. Drug Metab Dispos 31:1476–1480
Petushkova NA, Lisitsa AV (2012) Producing a one-dimensional proteomic map for human liver cytochromes p450. Methods Mol Biol 909:63–82
Rae JM, Johnson MD, Lippman ME et al (2001) Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 299:849–857
Anthérieu S, Chesné C, Li R et al (2010) Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab Dispos 38:516–525
Zhang T, Zhao M, Pang Y (2012) Recent progress on bioinformatics, functional genomics, and metabolomics research of cytochrome P450 and its impact on drug discovery. Curr Top Med Chem 12:1346–1355
Dopazo J (2013) Genomics and transcriptomics in drug discovery. Drug Discov Today. doi:10.1016/j.drudis.2013.06.003, pii: S1359-6446(13)00166-9
Sevior DK, Pelkonen O, Ahokas JT (2012) Hepatocytes: the powerhouse of biotransformation. Int J Biochem Cell Biol 44:257–261
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Pelkonen, O., Ahokas, J.T., Hakkola, J., Turpeinen, M. (2014). Consideration of Metabolism in In Vitro Cellular Systems. In: Bal-Price, A., Jennings, P. (eds) In Vitro Toxicology Systems. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-0521-8_22
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0521-8_22
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-0520-1
Online ISBN: 978-1-4939-0521-8
eBook Packages: Springer Protocols